BLAINJECTIONSOLUTION
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STIMUFEND (pegflilgrastim-fpgk) is a long-acting granulocyte colony-stimulating factor (G-CSF) analog administered by injection to stimulate white blood cell production. It is a biosimilar referencing filgrastim and is indicated for chemotherapy-induced neutropenia and related myelosuppressive conditions. The drug works by binding to G-CSF receptors on hematopoietic progenitor cells to promote their differentiation and proliferation.
Peak
Recently approved biosimilar in a competitive cytokine space; team focus likely on market penetration and payer contracts rather than expansion.
Mechanism of Action
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
STIMUFEND is in peak commercial lifecycle with moderate competitive pressure, meaning the brand team is focused on market share defense and payer negotiations rather than market expansion. Career growth opportunities are concentrated in commercial, market access, and operations functions; clinical and research roles are minimal post-approval.
Brand ManagerMedical Science Liaison
Worked on STIMUFEND at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.